RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.

导出 OA

翻译打印收藏纠错

作者： Sung-Hwa,Sohn ^[1] ; Hee Jung,Sul ^[1] ; Bohyun,Kim ^[1] ; Hyeong Su,Kim ^[2] ; Bum Jun,Kim ^[2] ; Hyun,Lim ^[2] ; Ho Suk,Kang ^[2] ; Jae Seung,Soh ^[2] ; Kab Choong,Kim ^[3] ; Ji Woong,Cho ^[3] ; Jinwon,Seo ^[4] ; Youngho,Koh ^[5] ; Dae Young,Zang ^[1]

作者单位： Hallym Translational Research Institute, Hallym University Sacred Heart Hospital, Anyang, 14066, Republic of Korea. ^[1] Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea. ^[2] Department of Surgery, Hallym University Medical Center, Hallym University Kangnam Sacred Hospital, Singil-ro Yeongdeungpo-gu, Seoul, 07441, Republic of Korea. ^[3] Department of Pathology, Hallym University Medical Center, Hallym University College of Medicine, Anyang-si, Gyeonggi-do 14068, Republic of Korea. ^[4] Department of Bio-medical Gerontology, Ilsong Institute of Life Sciences, Hallym University, Anyang, Gyeonggi-do, Republic of Korea. ^[5]

关键词 PWWP2B RNF43 docetaxel trihydrate gastric cancer pelitinib uprosertib

DOI 10.7150/jca.56014

PMID 34149925

发布时间 2021-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交